Daito Pharmaceutical Co.,Ltd. (4577.T)
JPY 2025.0
(0.75%)
JPY 2025.0
(0.75%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 8.71 Billion JPY | 75.86% |
| 2022 | 4.95 Billion JPY | 43.84% |
| 2021 | 3.44 Billion JPY | 1.56% |
| 2020 | 3.39 Billion JPY | 0.86% |
| 2019 | 3.36 Billion JPY | -37.88% |
| 2018 | 5.41 Billion JPY | -32.82% |
| 2017 | 8.06 Billion JPY | -16.43% |
| 2016 | 9.64 Billion JPY | -21.28% |
| 2015 | 12.25 Billion JPY | 1.65% |
| 2014 | 12.05 Billion JPY | -11.12% |
| 2013 | 13.56 Billion JPY | -5.08% |
| 2012 | 14.29 Billion JPY | 21.85% |
| 2011 | 11.73 Billion JPY | -2.62% |
| 2010 | 12.04 Billion JPY | -3.81% |
| 2009 | 12.52 Billion JPY | -7.43% |
| 2008 | 13.53 Billion JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 12.14 Billion JPY | 39.27% |
| 2023 Q2 | 7.84 Billion JPY | 77.48% |
| 2023 FY | 8.71 Billion JPY | 75.86% |
| 2023 Q3 | 7.3 Billion JPY | -6.93% |
| 2023 Q4 | 8.71 Billion JPY | 19.37% |
| 2023 Q1 | 4.42 Billion JPY | -10.81% |
| 2022 Q1 | 6.08 Billion JPY | 76.56% |
| 2022 FY | 4.95 Billion JPY | 43.84% |
| 2022 Q4 | 4.95 Billion JPY | -4.41% |
| 2022 Q3 | 5.18 Billion JPY | -7.61% |
| 2022 Q2 | 5.61 Billion JPY | -7.76% |
| 2021 FY | 3.44 Billion JPY | 1.56% |
| 2021 Q1 | 2.99 Billion JPY | -11.86% |
| 2021 Q2 | 2.62 Billion JPY | -12.2% |
| 2021 Q3 | 3.79 Billion JPY | 44.57% |
| 2021 Q4 | 3.44 Billion JPY | -9.22% |
| 2020 Q2 | 2.26 Billion JPY | -15.48% |
| 2020 Q3 | 3.77 Billion JPY | 66.54% |
| 2020 Q4 | 3.39 Billion JPY | -10.0% |
| 2020 Q1 | 2.67 Billion JPY | -20.39% |
| 2020 FY | 3.39 Billion JPY | 0.86% |
| 2019 Q3 | 3.51 Billion JPY | -12.05% |
| 2019 FY | 3.36 Billion JPY | -37.88% |
| 2019 Q4 | 3.36 Billion JPY | -4.22% |
| 2019 Q1 | 4.47 Billion JPY | -17.41% |
| 2019 Q2 | 3.99 Billion JPY | -10.72% |
| 2018 FY | 5.41 Billion JPY | -32.82% |
| 2018 Q3 | 7.37 Billion JPY | -0.53% |
| 2018 Q2 | 7.41 Billion JPY | -21.48% |
| 2018 Q1 | 9.44 Billion JPY | 17.15% |
| 2018 Q4 | 5.41 Billion JPY | -26.58% |
| 2017 Q2 | 9.2 Billion JPY | -9.4% |
| 2017 FY | 8.06 Billion JPY | -16.43% |
| 2017 Q4 | 8.06 Billion JPY | -10.67% |
| 2017 Q3 | 9.02 Billion JPY | -1.92% |
| 2017 Q1 | 10.15 Billion JPY | 5.28% |
| 2016 Q4 | 9.64 Billion JPY | -5.74% |
| 2016 FY | 9.64 Billion JPY | -21.28% |
| 2016 Q1 | 10.01 Billion JPY | -18.27% |
| 2016 Q3 | 10.23 Billion JPY | 6.12% |
| 2016 Q2 | 9.64 Billion JPY | -3.72% |
| 2015 Q4 | 12.25 Billion JPY | 17.66% |
| 2015 Q3 | 10.41 Billion JPY | 21.64% |
| 2015 Q2 | 8.56 Billion JPY | -12.55% |
| 2015 FY | 12.25 Billion JPY | 1.65% |
| 2015 Q1 | 9.79 Billion JPY | -18.78% |
| 2014 Q1 | 10.89 Billion JPY | -19.71% |
| 2014 Q3 | 9.17 Billion JPY | -4.25% |
| 2014 Q4 | 12.05 Billion JPY | 31.43% |
| 2014 FY | 12.05 Billion JPY | -11.12% |
| 2014 Q2 | 9.58 Billion JPY | -12.04% |
| 2013 Q1 | 10.59 Billion JPY | -25.9% |
| 2013 Q3 | 10.1 Billion JPY | -4.79% |
| 2013 Q4 | 13.56 Billion JPY | 34.29% |
| 2013 FY | 13.56 Billion JPY | -5.08% |
| 2013 Q2 | 10.61 Billion JPY | 0.18% |
| 2012 Q1 | 12.42 Billion JPY | 5.88% |
| 2012 FY | 14.29 Billion JPY | 21.85% |
| 2012 Q3 | 12.5 Billion JPY | 3.91% |
| 2012 Q2 | 12.03 Billion JPY | -3.1% |
| 2012 Q4 | 14.29 Billion JPY | 14.3% |
| 2011 Q1 | 11.03 Billion JPY | -8.42% |
| 2011 Q2 | 10.8 Billion JPY | -2.06% |
| 2011 FY | 11.73 Billion JPY | -2.62% |
| 2011 Q3 | 11.65 Billion JPY | 7.85% |
| 2011 Q4 | 11.73 Billion JPY | 0.67% |
| 2010 Q2 | 9.84 Billion JPY | 0.27% |
| 2010 Q4 | 12.04 Billion JPY | 13.54% |
| 2010 Q3 | 10.61 Billion JPY | 7.8% |
| 2010 FY | 12.04 Billion JPY | -3.81% |
| 2010 Q1 | 9.81 Billion JPY | 0.0% |
| 2009 FY | 12.52 Billion JPY | -7.43% |
| 2008 FY | 13.53 Billion JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 16.89 Billion JPY | 48.381% |
| Takeda Pharmaceutical Company Limited | 4843.75 Billion JPY | 99.82% |
| Sumitomo Pharma Co., Ltd. | 418.88 Billion JPY | 97.919% |
| Shionogi & Co., Ltd. | 11.62 Billion JPY | 24.966% |
| Wakamoto Pharmaceutical Co.,Ltd. | 100.52 Million JPY | -8573.119% |
| Nippon Shinyaku Co., Ltd. | 2.87 Billion JPY | -203.586% |
| Kaken Pharmaceutical Co., Ltd. | 3.85 Billion JPY | -126.468% |
| Eisai Co., Ltd. | 206.74 Billion JPY | 95.783% |
| Morishita Jintan Co., Ltd. | 425 Million JPY | -1951.529% |
| Hisamitsu Pharmaceutical Co., Inc. | 2.1 Billion JPY | -315.19% |
| Mochida Pharmaceutical Co., Ltd. | 369 Million JPY | -2262.873% |
| Fuso Pharmaceutical Industries,Ltd. | 12.72 Billion JPY | 31.465% |
| Nippon Chemiphar Co., Ltd. | 16.98 Billion JPY | 48.654% |
| Tsumura & Co. | 79.69 Billion JPY | 89.059% |
| Kissei Pharmaceutical Co., Ltd. | 1.72 Billion JPY | -404.864% |
| Torii Pharmaceutical Co., Ltd. | 244 Million JPY | -3473.361% |
| Towa Pharmaceutical Co., Ltd. | 202.35 Billion JPY | 95.691% |
| Fuji Pharma Co., Ltd. | 28.94 Billion JPY | 69.88% |
| Zeria Pharmaceutical Co., Ltd. | 47.58 Billion JPY | 81.677% |
| KYORIN Holdings, Inc. | 20.94 Billion JPY | 58.374% |
| Taiko Pharmaceutical Co.,Ltd. | 3.8 Billion JPY | -128.905% |
| SymBio Pharmaceuticals Limited | - JPY | -Infinity% |
| MedRx Co., Ltd | - JPY | -Infinity% |
| Mizuho Medy Co.,Ltd. | - JPY | -Infinity% |
| Solasia Pharma K.K. | 60 Million JPY | -14431.667% |
| Modalis Therapeutics Corporation | 412.5 Million JPY | -2013.697% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.48 Billion JPY | 8.076% |
| Sawai Group Holdings Co., Ltd. | 82.89 Billion JPY | 89.481% |
| Cyfuse Biomedical K.K. | 913 Million JPY | -854.984% |
| Toho Holdings Co., Ltd. | 30.24 Billion JPY | 71.171% |
| Koa Shoji Holdings Co.,Ltd. | 2.82 Billion JPY | -208.606% |